Sustained-release multiparticulates for oral delivery of a novel peptidic ghrelin agonist: Formulation design and in vitro characterization by Howick, Kenneth P. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Sustained-release multiparticulates for oral delivery of a novel peptidic
ghrelin agonist: Formulation design and in vitro characterization
Author(s) Howick, Kenneth P.; Alam, Ryan; Chruscicka, Barbara; Kandil, Dalia;
Fitzpatrick, Dara; Ryan, Aoife M.; Cryan, John F.; Schellekens, Harriët;
Griffin, Brendan T.
Publication date 2017-11-23
Original citation Howick, K., Alam, R., Chruscicka, B., Kandil, D., Fitzpatrick, D., Ryan,
A. M., Cryan, J. F., Schellekens, H. and Griffin, B. T. (2017) 'Sustained-
Release Multiparticulates for Oral Delivery of a Novel Peptidic Ghrelin
Agonist: Formulation Design and In Vitro Characterization',
International Journal of Pharmaceutics, 536(1), pp. 63-72. doi:
10.1016/j.ijpharm.2017.11.051





Access to the full text of the published version may require a
subscription.
Rights © 2017 Elsevier B.V. All rights reserved. This manuscript version is
made available under the CC BY-NC-ND 4.0 license.
http://creativecommons.org/licenses/by-nc-nd/4.0/
Embargo information Access to this article is restricted until 12 months after publication by
request of the publisher.






Title: Sustained-Release Multiparticulates for Oral Delivery of
a Novel Peptidic Ghrelin Agonist: Formulation Design and In
Vitro Characterization
Authors: Ken Howick, Ryan Alam, Barbara Chruscicka, Dalia
Kandil, Dara Fitzpatrick, Aoife M. Ryan, John F. Cryan,








Please cite this article as: Howick K, Alam R, Chruscicka B, Kandil D, Fitzpatrick D,
Ryan AM, Cryan JF, Schellekens H, Griffin BT, Sustained-Release Multiparticulates
for Oral Delivery of a Novel Peptidic Ghrelin Agonist: Formulation Design
and In Vitro Characterization, International Journal of Pharmaceutics (2010),
https://doi.org/10.1016/j.ijpharm.2017.11.051
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Sustained-Release Multiparticulates for Oral Delivery of a Novel Peptidic 
Ghrelin Agonist: Formulation Design and In Vitro Characterization  
Ken Howick a, b, c, Ryan Alama, Barbara Chruscickab, d, Dalia Kandilb, c, 
Dara Fitzpatricke, Aoife M Ryanc, f, John F Cryanb, d, Harriët Schellekensb, c, 
d, Brendan T Griffin* a, c. 
aSchool of Pharmacy, bDepartment of Anatomy & Neuroscience, cFood for 
Health Ireland, dAPC Microbiome Institute, eDepartment of Chemistry, 
Analytical and Biological Chemistry Research Facility (ABCRF), 
fDepartment of Food & Nutritional Sciences, University College Cork, 
Cork, Ireland. 
*corresponding author Dr. Brendan Griffin; brendan.griffin@ucc.ie; Tel: +353 21 
















There is an impetus to provide appropriate sustained release oral delivery vehicles 
to protect biofunctional peptide loads from gastric degradation in vivo. This study 
describes the generation of a high load capacity pellet formulation for sustained release 
of a freely water-soluble dairy-derived hydrolysate, FHI-2571. The activity of this novel 
peptidic ghrelin receptor agonist is reported using in vitro calcium mobilization assays. 
Conventional extrusion spheronization was then used to prepare peptide-loaded pellets 
which were subsequently coated with ethylcellulose (EC) film coats using a fluid bed 
coating system in bottom spray (Wurster) mode. Aqueous-based EC coating dispersions 
produced mechanically brittle coats which fractured due to osmotic pressure build-up 
within pellets in simulated media. In contrast, an ethanolic-based EC coating solution 
provided robust, near zero-order release in both USP Type 1 and Type 4 dissolution 
studies. Interestingly, the functionality of aqueous-based EC film coats was restored by 
first layering pellets with a methacrylic acid copolymer (MA) subcoat, thereby hindering 
pellet core swelling in acidic media. Broadband Acoustic Resonance Dissolution 
Spectroscopy (BARDS) was utilised as a complementary technique to confirm the results 
seen in USP dissolution studies. Retention of activity of the ghrelinergic peptide 
hydrolysate in the final encapsulated product was confirmed as being greater than 80%. 
The described pellet formulation is amenable to oral dosing in small animal studies in 
order to assess in vivo efficacy of the whey-derived ghrelinergic hydrolysate. In more 
general terms, it is also suitable as a delivery vehicle for peptide-based bioactives to 
special population groups e.g paediatric and geriatric. 
 
 














Oral peptide delivery remains a bottle-neck in the transition of potentially 
effective therapeutics from bench to bedside (Brayden and Alonso, 2016). Bioavailability 
of peptides is consistently poor due to the acidic and enzyme-mediated degradation in gut 
lumen, leading to loss of efficacy. The rapid degradation of bioactive peptide structures 
in vivo necessitates drug delivery technologies which protect the payload in the gastric 
compartment and allow for site specific delivery to the small and large intestine (Malik 
et al., 2007). Various formulation approaches have been adopted to protect peptides from 
degradation within the gastrointestinal tract and increase oral bioavailability, ranging 
from standard formulations containing functional excipients, to micro- and nano- based 
(colloidal) delivery systems (Lakkireddy et al., 2016). However, commercial success in 
terms of an orally active peptide formulation has been limited to a few niche, high potency 
peptides which can achieve therapeutic efficacy with limited bioavailability (i.e. <1%) 
(Aguirre et al., 2016). Micro- and nano-based delivery systems encompass a large 
proportion of the efforts to translate peptide functionality in vitro to the clinical setting. 
However, various limitations exist to these respective approaches: the former typically 
involves complex processing steps leading to peptide degradation (Witschi and Doelker, 
1998; Yin et al., 2008), while the latter displays poor loading capacity (1-5%), variable 
release characteristics and limited scalability (Jain et al., 2008; Redhead et al., 2001). 
Furthermore, stresses during processing, including shear forces, exposure to organic 
solvents and excessive drying time will adversely impact on peptide stability, as well as 
interactions with hydrophilic/hydrophobic interfaces. There is thus an impetus to develop 
more suitable oral delivery platforms to enable assessment of in vivo efficacy for peptidic 













The main aim of this study is the encapsulation of a novel bioactive peptide using 
a traditional multiparticulate formulation approach. These coated pellets are intended for 
use pre-clinically to investigate bioactive functionality in rodents. In addition, from a 
clinical utility perspective, pelletised dosage forms offer numerous advantages such as 
flexible dosing and ease of administration in special population groups. Conventional 
formulations such as coated pellets are widely used in the pharmaceutical industry to 
obtain suitable release profiles for a variety of active pharmaceutical ingredients (API) 
(Lecomte et al., 2004; McGinity and Felton, 2008) . Millimetre size-range pellets have 
notable advantages compared to sub-micron and colloidal delivery approaches. A 
narrower particle size distribution allows for homogeneous film formation and more 
reproducible release profiles. Higher peptide loading can typically be achieved by 
inclusion of a pelletisation aid such as microcrystalline cellulose. The process is readily 
scalable to industrial size, while critically this represents a flexible dosing platform 
ranging from pre-clinical proof of concept studies, to clinical dosing in special population 
groups, i.e. paediatric and geriatric patients. Fluid bed coating technology holds many 
advantages for coating peptide-loaded matrix pellets. This is a well-established process 
that allows for simple and efficient polymer layer deposition and subsequent reliable 
delayed/sustained drug release, depending on the nature of the functional polymeric coat 
applied. Furthermore, the processing conditions are mild relative to other methods such 
as pan coating, while low weight gains achieve reliable, uniform coating. Typically, 
pellets are fluidized by high flow air, while an atomized coating solution or suspension is 
pulsed onto the pellets. As liquid coating material is deposited and simultaneously dried, 
the latent heat of evaporation of solvent means that the microenvironment of each 
individual pellet is considerably lower than the pre-heated inlet air (El Mafadi et al., 2005; 













The therapeutic potential of bioactive peptides for treating many health problems, 
including appetite-related disorders, is becoming increasingly apparent (Torres-Fuentes 
et al., 2015). Recent work in rodents has demonstrated the ability of whey protein isolate 
to reduce the expression of satiating genes in the hypothalamus, thereby increasing energy 
intake (Nilaweera et al., 2017). This study describes a novel peptidic dairy hydrolysate, 
FHI-2571, with ghrelin receptor agonist activity. Ghrelin, a 28-amino acid containing 
peptide, is produced in the stomach and functions as an endogenous appetite-stimulant 
(Howick et al., 2017; Kojima et al., 1999; Nakazato et al., 2001).  The ghrelin receptor 
has thus been a pharmacological target to reduce appetite in obesity as well as to stimulate 
food intake in conditions of malnutrition and cachexia (wasting syndrome) (Howick et 
al., 2017; Schellekens et al., 2010). While the precise site of action of ghrelin is still open 
to some debate (Howick et al., 2017), the high prevalence of the ghrelin receptor 
throughout the small and large intestinal mucosa is thought to facilitate communication 
with appetite centres in the brain via the vagus nerve (Date, 2012), and thus may hold 
potential as a local therapeutic target (Lakkireddy et al., 2016).  
Overall, this study aims to first assess the in vitro efficacy of a novel ghrelin receptor 
agonist, FHI-2571, and investigate a formulation approach to progress this bioactive to in 
vivo studies. To overcome the acidic and proteolytic degradation of this whey-derived 
hydrolysate in the stomach and upper intestine, we have developed a sustained-release 
oral delivery system to minimise exposure to gastric acid and intestinal peptidases. In 
vitro release profiles of FHI-2571 in traditional USP dissolution tests, confirmed using 
BARDS, demonstrate the capability of our formulation approach in achieving prolonged, 
elevated levels of bioactive throughout the small intestine in vivo. Activity assays confirm 














2 Materials and Methods 
2.1 Materials 
Dairy-derived peptide hydrolysate (FHI-2571) was provided by Food for Health 
Ireland (see section 2.2). Methacrylic acid and ethyl acrylate copolymer type C (MA, 
Acryl-EZE® II) and ethylcellulose (EC) (Ethocel™ Standard 20 Premium) were both 
purchased from Colorcon Corp., Dartford, Kent, UK, while aqueous pseudo-latex of EC 
(Surelease® Type B NF) was sourced from Colorcon Corp., Indianapolis, IN, USA. 
Microcrystalline cellulose (MCC, Avicel® PH-101 NF Ph. Eur.) was purchased from 
FMC Corp., Little Island, Cork, Ireland. Pharmaceutical grade ethanol 96% (v/v) was 
procured from Carbon Chemicals Group Ltd., Ringaskiddy, Cork, Ireland. Unless 
otherwise stated, only deionised water was used in this study. For the Ca2+ mobilisation 
assays, fetal bovine serum (3.3%) was obtained from Sigma-Aldrich, Arklow, Wicklow, 
F7524. Assay buffer was composed of 1x Hanks balanced salt solution, HBSS, Gibco™ 
14065049 (Thermo Fisher Scientific™), containing 20 mM HEPES (Sigma-Aldrich, 
Arklow, Wicklow, H0887). The endogenous agonist, ghrelin (rat), was supplied by Tocris 
Bioscience, Avonmouth, Bristol, UK (Cat. No. 1465). 
2.2 Generation of FHI-2571 
A dairy-peptide hydrolysate was prepared by a method similar to a previously 
published method (Mukhopadhya et al., 2015). Briefly, bovine milk derived whey protein 
(80 % w/w protein, Carberry Group, Ballineen, Cork, Ireland) was suspended at 10 % 
protein (w/w) in reverse osmosis-treated water and agitated continuously at 50 °C for 1 h 
in a jacketed tank. The pH was adjusted using a NaOH 4.0 N solution (VWR, Dublin, 
Ireland). A bacterial food-grade enzyme preparation, was added to the protein solution 













heat-treatment and the resultant hydrolysate solution was dried in a Niro TFD 20 Tall-
Form Dryer (GEA, Düsseldorf, Germany). 
 
2.3 Ca2+   mobilisation assay for peptide ghrelin receptor activity pre- and post-
encapsulation 
Ghrelin receptor mediated changes in intracellular Ca2+ mobilisation were 
monitored on a FLIPR Tetra High-Throughput Cellular Screening System (Molecular 
Devices Corporation, Sunnyvale, California, USA). Ca2+ mobilisation assays were 
performed according to the manufacturer’s instructions and modified from a previously 
described method (Pastor-Cavada et al., 2016). Human Embryonic Kidney (HEK293A) 
cells stably transfected with the ghrelin receptor were seeded in black 96-well microtiter 
plates at a density of 3 x 104 cells/well and maintained overnight at 37 °C in a humidified 
atmosphere containing 5 % CO2. Twenty-four hours before the experiment, media was 
replaced with serum-free media containing 1 % non-essential amino acids (NEAA). On 
experimental day cells were incubated with 80 µL of 1xCa5 dye in assay buffer (1x Hanks 
balanced salt solution - HBSS, supplemented with 20 mM HEPES buffer) according to 
the manufacturer’s protocol (R8141, Molecular Devices Corporation, Sunnyvale, CA). 
Addition of compound (40 µL/well) was performed by the FLIPR Tetra, and fluorescent 
readings were taken for 120 seconds at excitation wavelength of 485 nm and emission 
wavelength of 525 nm. The relative increase in cytosolic Ca2+ was calculated as the 
difference between maximum and baseline fluorescence and depicted as percentage 
relative fluorescent units (RFU) normalized to maximum response (100 % signal) 
obtained with 3.3 % fetal bovine serum (FBS). Background fluorescence was recorded in 
cells in assay buffer alone and subtracted from RFUs.  All compounds and hydrolysates 
used in experiments were prepared in assay buffer. FBS (3.3 %) and the endogenous 













were considered as positive when Ca2+ influx exceeds 20% compared to control. Data 
were analysed using GraphPad Prism software (PRISM 5.0; GraphPAD Software Inc., 
San Diego, California, USA). Sigmoidal concentration-response curves were generated 
using nonlinear regression analysis with variable slope. 
 
 
2.4 Pellet preparation by extrusion-spheronisation 
Initial process optimisation studies, focusing on pellet production, trialled a range 
of different ratios of FHI-2571 to MCC (50:50, initially). The gradual reduction of FHI-
2571 content from 50% afforded a robust pellet with minimal generation of fines at 33% 
peptide loading (data not shown). Therefore, requisite quantities of FHI-2571 and MCC 
were combined in a ratio of 33:67, respectively, and manually blended for 1 minute. The 
powder was then added to a Kenwood Major planetary mixer (KM005, Kenwood Ltd., 
Hampshire, UK), fitted with a ‘K’ blade mixing arm, and dry blended at minimum setting 
for 5 minutes. The resultant dry powder blend was granulated by addition of deionised 
H2O, under constant agitation by planetary mixer at minimum setting. A homogenous 
dispersion of moisture was ensured, by adding deionisedH2O periodically from an 
atomizer every 15 seconds. Mixing was stopped every 2-3 minutes, to scrape material 
down from the sides of the mixing vessel. The granulation end-point was achieved upon 
addition of a cumulative amount of deionisedH2O equivalent to 45 % (w/w) of the dry 
powder blend.  The granulate was immediately extruded at an extrusion speed of 17 – 19 
rpm using a sieve extruder (Caleva® Extruder 20, Caleva Process Solutions, Sturminster 
Newton, Dorset, UK). Both the screen thickness and aperture diameter were 1 mm. The 
extrudate was subsequently spheronized for 1.5 minutes at a speed of 1500 rpm, using a 













equipped with a cross-hatch friction plate having a diameter of 22.5 cm. Resulting pellets 
(c. 100 g) were dried in a laboratory scale microfluid bed system (Vector Corp., Marion, 
IA, USA) at 40 °C for 20 minutes and then stored at room temperature in an airtight 
container until further testing took place.  
 
 
2.5 Pellet film coating 
Film coating was performed in a laboratory scalemicrofluid bed system, equipped 
with a Wurster funnel insert, in bottom-spray mode. Both nozzle air (16.6 – 16.7 psig) 
and airflow (310 – 335 L/minute) were adjusted to maximum setting. Liquid feed rate 
(gram/minute) and spray pattern parameters varied, depending on the film coating 
polymer mixture (see Table 1). Various coating polymer mixtures were prepared; a 
concentrated 25 % (w/w) aqueous pseudo-latex of EC (Surelease® Type B) was diluted 
to 11 % (w/w), using deionised H2O water. Dissolution of EC (Ethocel™ Standard 20 
Premium) in 96 % (v/v) EtOH to produce a 5 % (w/w) ethanolic EC polymer coating 
solution was performed slowly under conditions of vigorous agitation. Dry methacrylate 
powder (Acryl-EZE® II) was gradually dispersed in deionised H2O water to produce a 
10 % (w/w) coating mixture. All of the coating polymer mixtures were subjected to 
constant agitation at 900 rpm, for not less than 30 minutes, using a magnetic stirrer at 
room temperature. Agitation of the polymer coating mixtures (750 – 850 rpm at room 
temperature) was maintained during film coating procedures. Uncoated pellets were 
charged to the coating vessel (25 – 50 g, pellet load), and the coater reassembled. Pellets 
were pre-heated in-situ, for approximately 10 minutes (inlet air temperature 80 °C; outlet 













polymer required for film coating was based on a pre-determined weight gain, based on 















The duration of the film coating process was determined by the theoretical 
percentage of coating required, and the dry weight of pellets added to the spray coater. 
The vessel containing the coating polymer mixture was weighed before and after the 
coating process, to determine the actual weight of coating solution sprayed onto the 
pellets. The microfluid bed coating system was visually monitored to ensure that a steady 
uniform flow of pellets was maintained within the spray chamber.  
 
 
2.6 pH susceptibility tests 
Powdered FHI-2571 (6 g) was dissolved in 100 ml of deionised H2O and aliquoted 
into 4 x 25 ml samples. Next, 3 M HCl was added to bring the individual solutions to the 
requisite pH (pH 1, 3, 5 and untreated), using a pHenomenal® 1000L pH meter with a 
pHenomenal® 221 pH electrode. After pH was adjusted, samples were incubated for 30 
minutes under gentle agitation. Finally, 50 µL of each sample was removed and added to 
950 µL of Ca2+ assay buffer and neutralization of acidic pH confirmed before samples 
were added to cells. 
2.7 In vitro dissolution tests 
USP Type 1 (Basket) Dissolution studies:  
Dissolution testing (USP Type 1) was performed, using a basket-type dissolution 
apparatus (DISTEK, Inc., Model 2100C, North Brunswick, NJ, USA) with 500 mL of 
both simulated gastric fluid sine pepsin (SGFsp) (pH 1.2) and simulated intestinal fluid 
sine pancreatin (SIFsp) (pH 6.8) as dissolution media. Dissolution bath temperature was 
maintained at 37 ± 0.5 °C. Impeller shaft speed was 50 rpm. Dissolution medium  













and 360 minutes) from a location not less than 1 cm from the vessel wall and midway 
between the top of the rotating impeller and dissolution media surface. After sampling, 
an equal volume of dissolution medium  was added to the dissolution vessel.  













USP Type 4 (Flow-through) Dissolution studies:  
An Erweka® flow-through apparatus (Model DFZ 720, ERWEKA GmbH, 
Germany), equipped with a HKP 720 piston pump and 22.6 mm diameter cells, was used 
to perform USP type 4 dissolution studies. The temperature of the water bath was 
maintained at 37 °C. Experiments were carried out over six hours using the closed loop 
system at a flow rate of 4 ml/minute. The dissolution media was composed of 100 mL 
SGFsp for the first two hours. SGFsp was then replaced with 100 mL of SIFsp, after two 
hours. Samples (1 mL) were taken at the same time intervals as for USP Type 1 
dissolution (described above).. After sampling, an equal volume of dissolution medium  













2.8 Peptide quantification assay 
The bicinchoninic acid (BCA) assay was performed using a BCA assay kit 
(Thermo Fisher Scientific™ Pierce™ BCA Protein Assay, Catalog Number 23225) 
according to a previously published method.  Diluted stock samples were made using a 2 
mg/ml stock solution of FHI-2571 in SGFsp. Using this stock solution, a serial dilution 
was performed to afford six 0.1 mL solutions with concentrations of 2, 1, 0.5, 0.25, 0.125, 
and 0.0625 mg/mL, respectively. This method was repeated, using SIFsp. A 25 µL 
volume of each sample obtained during dissolution testing (see section 2.6.) was then 
transferred to a 96-well plate. After the dissolution experiment was completed, peptide 
not released from the formulation was determined. Remaining pellets were removed, 
physically crushed and redissolved in the relevant media. The quantity of liberated 
peptide  was determined using the BCA assay. Working reagent was prepared by mixing 
BCA assay Reagent A with BCA assay Reagent B in a ratio of 50:1. The working reagent 
(200 µL) was then transferred to each well. The plates were then covered and incubated 
at 37 °C for 30 minutes. Spectrophotometric analysis (Flexstation II Multiplate 
Fluorometer, Molecular Devices, Sunnyvale, California) was performed at 562 nm. A 
standard curve was made by plotting the average blank-corrected absorbance (562 nm) 
for each BCA assay standard versus concentration (mg/mL). The standard curve was used 
to determine the protein concentration of each unknown sample. 
2.9 Electron microscopy 
Samples were mounted onto aluminium stubs using double sided carbon tape. All 
samples were sputter coated with a 5 nm layer of gold palladium (80:20) using a Quorum 
Q150 RES Sputter Coating System (Quorum Technologies, UK), before being examined 













BioSciences Imaging Centre, Department of Anatomy & Neuroscience, UCC. Digital 
electron micrographs were obtained of areas of interest. 
2.10 Broadband Acoustic Resonance Dissolution Spectroscopy 
A Broadband Acoustics Resonance Dissolution Spectroscopy (BARDS) , as 
described previously by Fitzpatrick et al. (Fitzpatrick et al., 2014) was used to investigate 
the BARDS responses (BARDS ACOUSTIC SCIENCE LABS, Cork, Ireland). A sample 
size of 0.1 g was used in each experiment. Testing was performed under acidic conditions, 
using 25 mL simulated gastric fluid (SGFsp pH 1.2) as solvent. The stirrer rate was set to 
300 rpm. Prior to testing, temperature (c. 25.5 °C), relative humidity (c. 47%), and 
pressure (c. 1025 mbar) were recorded. Before sample addition, steady state resonances 
were recorded for 30 s, while the magnetic follower was in motion. Spectra were recorded 
using a microphone (Sony ECM-CS10, range 100 Hz – 16 kHz) for 560 – 1300 s. The 
frequency time course of the fundamental frequency curve is shown as manually extracted 
data from the recorded acoustic response. All experiments were performed in triplicate (n 
= 3) and average values with error bars representing the standard deviation are presented.  
2.11 Data Analysis 
Data were analysed and graphs generated using both GraphPad Prism software 
and Microsoft Excel software. All means were calculated from the results of at least three 
independent experiments carried out in triplicate. For the in vitro calcium mobilization 
assays, standard error of the mean (SEM) is depicted, while all dissolution results report 



















The activity of the whey-derived hydrolysate, FHI-2571, on the ghrelin receptor 
was shown using intracellular Ca2+ mobilization, as a measure of downstream ghrelin 
receptor signalling activation (Schellekens et al., 2013), in HEK293A cells (human 
embryonic kidney cells) stably expressing the ghrelin receptor tagged with an enhanced 
green fluorescent protein (GHSR-1a-EGFP) (Figure 1A). FHI-2571 hydrolysate 
stimulated calcium mobilization in cells expressing ghrelin receptor in a concentration-
dependent manner, with the EC50 = 1.1mg/ml and efficacy (Emax) reaching 205%.  The 
potency of FHI-2571 is 1000-fold lower compared to the endogenous receptor ligand, 
ghrelin (EC50 = 2.84µg/ml). Interestingly, the maximal response attained for FHI-2571 
hydrolysate is higher compared to ghrelin (Emax = 150%). Efficacy of both compounds 
was normalised to the maximal response of the positive control (3.3% FBS, Emax = 100%). 
Critically, the concentration response curve shows that the FHI-2571 hydrolysate has 
ghrelin receptor agonist activity, while the un-hydrolysed parent whey protein 
concentrate (WPC) fails to elicit appreciable activity in the same assay (Figure 1A). 
Furthermore, no Ca2+ influx was observed in wild-type HEK293A cells (HEK293A-WT) 
not expressing the ghrelin receptor, when exposed to the FHI-2571 hydrolysate, while 
treatment with control (FBS) resulted in a non-specific maximal intracellular Ca2+   
mobilization in this cell line (Figure 1B), indicating the specificity of FHI-2571 activity 


















The FHI-2571 hydrolysate was exposed to varying degrees of acidic pH for a time 
representative of minimum gastric residence time in the fasted state (minimum 30 minutes 
(Tuleu et al., 1999)). A pH dependent loss in peptide activity is observed for the whey-
derived FHI-2571 (Figure 2), confirming the requirement for a protective film coat to 
minimise exposure to gastric acid before progression to in vivo efficacy studies.  
3.3 Aqueous-based Ethylcellulose dispersion yields a mechanically weak film 
coating 
USP Type 1 (Basket) dissolution studies were carried out in both simulated gastric 
conditions (simulated gastric fluid, SGFsp, pH 1.2) in order to assess the release profile 
of peptide from the pellets. Pellets displayed burst release of the peptide, with > 80 % 
release over the first 60 minutes. This occurred independent of coating thickness, as 10 
% coating represented no additional benefit to the 5 % (Figure 3). Visual investigation 
showed film disintegration or “shelling” occurred within 20 minutes of exposure to the 
aqueous medium. This was attributed to the relatively low mechanical strength of the film 
coat produced from aqueous dispersion-based fluidized coating (Lecomte et al., 2004; 
Siepmann et al., 2008). An aqueous-based dispersion is hence an unsuitable coating 














3.4 Towards pellet coating achieving sustained release of peptide - Ethanolic 
solutions of ethylcellulose vs. aqueous dispersion based dual-coat 
Two alternative strategies were employed to circumvent the observed film 
disintegration for EC coats prepared using aqueous-based EC dispersions (Figure 4). 
Firstly, an ethanolic solution of EC was prepared and applied to the pellets. The EC coated 
pellets prepared from ethanolic solutions achieved near-zero order delayed release in 
simulated USP Type 1 (Basket) dissolution studies carried out in SGFsp.  Due to the 
drawbacks associated with organic solvent use (Muschert et al., 2009; Srivastava and 
Mishra, 2010), an aqueous-based dual coat approach was trialled as an alternative. A pH-
resistant methacrylic acid copolymer subcoat was applied to the pellets in order to prevent 
water ingress to the pellet core under acid conditions.. Interestingly, this aqueous-based 
dual coat approach achieved a similar delayed release profile as the organic EC coat. 
 







Figure 5 represents SEM images of uncoated, aqueous EC coated, ethanolic EC 
coated and dual-coated pellets (A, B, C & D, respectively). Notably, images reveal no 
obvious structural cracks or pores on the surface of the coated pellets which may explain 
the fluid ingress and film coat rupture in the aqueous-based EC coated pellets. Figure 6 
presents the SEM images obtained from cross-sectioned pellets with the various film 
coats. The aqueous EC coated pellet displays a porous cross-sectioned coat (Figure 6B). 













(Figure 6F). By contrast, the ethanolic-based EC coat is distinctly non-porous and waxy 
in appearance (Figure 6D) while the methacrylate-based subcoat is also visibly non-
porous (Figure 6F). The porous nature of the aqueous-based EC coat is likely responsible 
for the osmotic-induced fluid ingress to the pellet core, and subsequent film 
disintegration. Both the ethanolic based EC coat and the methacrylate based subcoat are 
functionally resistant to water ingress in simulated gastric conditions. This is attributable 
to the non-porous substructure evident in the photomicrographs. 
 
3.6 Investigation of peptide release in pH transfer model  
A pH transfer model was utilised in order to investigate whether there was any 
appreciable difference in release when intestinal pH was introduced to the pellets after 2 
hours exposure to SGFsp (pH 1.2) conditions (Figure 7). Predictably the aqueous EC-
coated pellets display a burst release of peptide with > 80 % release in the first hour. 
Notably, the dual-coated EC pellets retain a sustained release profile after the transition 
from acid pH, to intestinal pH (pH 6.8). In contrast to the release profiles observed under 
USP Type 1 conditions, the ethanolic-based EC coat also displays a faster release rate 
compared to the dual-coat.. This difference in release patterns between Type 1 and Type 
4 may be attributed to different flow patterns and agitation between the systems. 
 
3.7 Broadband Acoustics Resonance Dissolution Spectroscopy (BARDS) 
 
As expected in the case of uncoated pellets, a distinct change in real-time 
compressibility of the solvent is evident immediately after addition of the pellet to the 
solvent with the fundamental curve approaching its respective frequency minimum within 













lacking a protective film coat. In the case of both the dual-coated pellets and organic-
based EC-coated pellets, there is no noticeable dissolution/disintegration event, following 
addition to the acidic solvent in the vessel (SGFsp pH 1.2). This spectral observation was 
confirmed by visual inspection; both the dual-coated pellets and organic-based EC-coated 
pellets remained intact during testing and no disintegration was observed. In the case of 
the aqueous-based EC coated pellets, a distinct change in solvent compressibility was 
observed from 400 seconds, indicating that the coated pellets undergo a 
dissolution/disintegration event here under acidic conditions. This was also evident 
visually in the solvent vessel with pellets undergoing disintegration.  The aqueous-based 
EC coated pellets demonstrated a lag time, prior to disintegration, where the frequency 
minimum is observed at 780 seconds. This result indicates that the aqueous-based EC 
pellets do not remain intact in an acidic environment and further support findings from 
previous dissolution experiments (see Figure 3A, 4, and 7). 
 
3.8 Ghrelin receptor activity post-encapsulation 
In order to quantify the impact of processing conditions on bioactivity of the 
peptide cargos, activity of the encapsulated peptide in vitro was reassessed. Activity of 
the FHI-2571 hydrolysate liberated from the encapsulated product was determined 
relative to activity of non-encapsulated FHI-2571 peptide in the ghrelin receptor 
overexpressing cells, as before. Activity was quantified as being greater than 80% for 

















Dairy-derived peptides are increasingly recognised for their bioactive components 
which may bestow clinical benefits (Hartmann and Meisel, 2007; Torres-Fuentes et al., 
2015). Peptides fractions have been isolated with ACE-inhibitory action, and blood-
pressure lowering properties of these dairy-derived bioactives in vivo have been reported. 
Furthermore, a casein-derived bioactive fraction with specific serotonin-2C receptor (5-
HT2C) agonist activity eliciting satiating properties in a rodent model has been described 
(Schellekens et al., 2014). Ghrelin and the growth hormone secretagogue receptor 
(GHSR-1a) or ghrelin receptor, play an important role in energy balance and appetite 
regulation (Howick et al., 2017; Schellekens et al., 2010). Many studies have reported 
potent appetite-stimulating effects of both peripheral and central administration of ghrelin 
(Tschop et al., 2000; Wren et al., 2001). In this study, we identified a milk whey-derived 
hydrolysate with intrinsic ghrelin receptor agonist activity. The dairy hydrolysate, FHI-
2571, dose-dependently and specifically increased intracellular Ca2+ in HEK293A cells 
heterologously expressing the ghrelin receptor in vitro, while the unfractionated parent 
whey elicited negligible effects on the receptor (Figure 1A). In vivo, the ghrelin receptor 
is present throughout the small and large intestine, acting remotely via the vagus nerve to 
communicate with appetite centres in the brain (Date, 2012; Date et al., 2000). Given the 
appropriate oral delivery mechanism, a potential to increase food intake in vivo by 
targeting intestinal ghrelin receptor therefore exists.  
Given the acidic and peptidase rich environment of the gastrointestinal tract, as 
well as the barriers to epithelial absorption, development of appropriate delivery 
platforms to improve in vivo efficacy of bioactive peptides is required (Brayden and 
Alonso, 2016; Gleeson et al., 2016). Microspheres and microcapsules are one such 













(Witschi and Doelker, 1998; Yin et al., 2008). Furthermore, there is an ever-increasing 
interest in nano-sized formulations (Date et al., 2016). Nano-based approaches offer a 
platform to traverse membrane barriers and deliver peptide drugs in a targeted manner, 
increasing oral bioavailability and favourably altering pharmacokinetic profiles (Griffin 
et al., 2016). However, much work remains to be done in order to elucidate the 
mechanisms of action and safety profiles of nano-formulations. Critically, despite the 
exciting advances in the micro- and nano- fields, none are yet proven as a viable, 
industrially scalable delivery approach to achieve both high loading of peptide, and a 
predictable release pattern. On the other hand, there are limited examples of conventional 
mm-sized pellets being used to deliver peptide payloads, despite the approach being 
widely used in formulation of small organic drug molecules. This is traditionally due to 
the poor permeation of peptides across the intestinal barrier, extensive first-pass 
metabolism and short half-life in the body, not to mention the high concentration of 
peptidases present in the upper small intestine. In the case of the bioactive peptide under 
investigation here, FHI-2571, its pharmacological target, the ghrelin receptor, is found 
throughout the small and large intestine on vagal afferent terminals located just beyond 
the mucosal brush border (Date et al., 2000), while a substantial proportion of the 
hydrolysate size fraction is < 1 kDa, meaning that paracellular transit to these nerve 
terminals is possible (Griffin and O'Driscoll, 2011). The ghrelin receptor is also located 
in the myenteric plexus of rodent and human gastrointestinal tract (Takeshita et al., 2006), 
furthering the case for enhancing the delivery of the peptidic payload to the intestinal 
lumen. Therefore, we sought to develop a simple, high loading sustained release delivery 
vehicle to protect the ghrelinergic peptide from acid exposure in the gastric compartment 













Firstly, the need for a gastro-protected delivery vehicle was validated by exposing 
FHI-2571 to acidic pH, which predictably abolished the bioactivity of this compound on 
the ghrelin receptor in a progressive manner (Figure 2). Polymeric film coating of active 
pharmaceutical ingredient (API)-loaded core pellets  has been widely utilised, with 
predominantly aqueous based functional polymer coatings (Siepmann and Siepmann, 
2013).  EC is the most commonly-used coating polymer. It is non-toxic and 
biodegradable, and achieves predictable, pH independent release profiles due to drug 
diffusion across a water-insoluble membrane (Ozturk et al., 1990). Generally, aqueous 
EC colloidal dispersions are preferred as a coating medium due to safety and 
environmental reasons (Muschert et al., 2009; Srivastava and Mishra, 2010). Moreover, 
it is possible to achieve higher percentages of solid content in aqueous dispersions; the 
high viscosity of organic solutions of EC is a limiting step for coating media (Lecomte et 
al., 2004). Therefore, coating time can be excessively lengthened when organic solutions 
are used. 
In our study, aqueous-based EC dispersion failed to provide us with a sufficiently 
robust film coating during release testing. Burst release of peptide was observed (> 80 % 
in the first 60 minutes) in USP Type-1 and USP-Type 4 apparatus. Macroscopic and 
microscopic investigation showed that the polymer coating fractured after exposure to 
aqueous media, allowing peptide to freely-diffuse out of the matrix system though fluid-
filled cracks, rather than diffusing through the polymeric coat. This was attributed to the 
mechanism of film coat formation for a coating dispersion. During the fluid bed coating 
process, evaporation of solvent on the surface of the particles leads to sequential, layered 
polymer chain packing. These discrete polymer particles interact with one another via 
relatively weak Van der Waals interactions. Aqueous solubility is a major factor affecting 













pressure is a driving force for water ingress into pellets, increasing the intra-particulate 
volume and outward pressure on the coating film. Furthermore, migration of API into the 
film coat during the fluid-bed coating process has also been reported (Melegari et al., 
2016). Therefore, the high aqueous solubility of the peptide may lead to leaching into the 
EC coat, creating water soluble pores which affords easier ingress of water into the pellet 
core, thereby causing swelling and an increased intra-particulate pressure. Considering 
the high loading of peptide in our system (33%), this problem is compounded leading to 
pellet swelling and film fracture. 
Here, we demonstrate the mechanical integrity of two alternative film coating 
approaches, which both provide time-dependent release of a bioactive peptide in the in 
vitro setting. This is particularly useful in the context of sustained delivery of hydrophilic 
peptides. Initial burst release has been reported from some reservoir devices, which tapers 
over time due to a reducing concentration in the reservoir (Dekyndt et al., 2015). Organic 
solutions of the film coating polymer lead to greater mechanical strength in the resulting 
coat. This is due to the fluid movement of the polymer chains in solution, which, upon 
removal of the solvent phase, cross-link and form a robust, physically-bonded polymeric 
meshwork (Lecomte et al., 2004). This is  supported by SEM images (Figure 6) which 
show a distinct porous nature to the cross sectionedaqueous-based film coat (Figure 6B), 
compared to a more complete, non-permeable structure seen in the ethanolic-based film 
coat (Figure 6D). Consistent with the impervious nature of the coat show in SEM cross-
sections, FHI-2571 -loaded pellets coated with an ethanolic solution of EC displayed 
near-zero order release in both USP Type 1 (Basket) and USP Type 4 (Flow-through) 
dissolution setups (Figures 4 & 7).  
Due to the drawbacks associated with organic-based coating solutions, an aqueous 













desirable. Increased efficiency of aqueous EC film coats has been demonstrated by 
allowing a curing step to take place post-encapsulation, which typically involves 
extended periods of exposing the product to high temperature and humidity – water is an 
efficient plasticizer for many polymers (Kucera et al., 2013; Siepmann and Siepmann, 
2013). However, in this study an extended period of exposure to such harsh conditions 
was not possible due to the probability of peptide hydrolysis. Furthermore, layered multi-
particulates have been used successfully by Siepmann and colleagues to provide reliable 
zero-order release of water-soluble agents (Dekyndt et al., 2015). However, this involved 
incorporating the drug into the film coating layer itself. The potential to incorporate a 
peptide-based bioactive into such coating solutions, rather than the pellet matrix itself, is 
limited due to high risk of denaturation.  
Dual coated pellets have been used before to increase the functionality of the outer 
coat and optimise release profiles. In this study, an acid resistant methacrylic acid (MA) 
co-polymer was proposed, which was layered beneath the aqueous EC coat in order to 
provide an impermeable seal-coat in acid conditions. This may be considered atypical, 
given that a pH dependent polymer would normally form the outer layer in dual-coated 
systems. The acid-resistant layer was initially trialled as an overcoat of the aqueous EC 
coating, which limited burst release in acid conditions. However, upon transition to 
intestinal pH conditions, immediate dissolution of the MA overcoat occurred, with 
subsequent “shelling” of the EC subcoat (data not shown). This was due to the swelling 
of the pellet core combined with the mechanically brittle subcoat formed by the aqueous-
based EC dispersion. USP-Type 1 dissolution studies for our dual-coated pellets in SGFsp 
display a near-zero order release profile comparable to organic EC pellets (Figure 4). This 
is consistent with the insolubility of methacrylic acid below pH 5.5, which likely 













film fracture. Furthermore, USP-Type 4 dissolution studies, also show a delayed release 
profile after transitioning to intestinal media (pH 6.8) (Figure 7). This may be considered 
surprising given the solubility of the methacrylate copolymer above pH ~ 5.5. The intact 
EC overcoat in this case is likely hindering the access of the intestinal buffer to the surface 
of the subcoat, thereby reducing the rate at which the subcoat can dissolve.  The advantage 
to the MA applied as a subcoat is therefore two-fold, initially it prevents the ingress of 
fluid to the pellet core and subsequent pressure-induced film fracture. Secondly, the 
limited exposure of intestinal media to the MA subcoat due to the intact EC overcoat 
serves to slow the overall dissolution of the film coat. 
BARDS was utilised to confirm the release profiles obtained from the compendial 
dissolution methods (Figure 8). This is an emerging technology used to explore the 
changes in compressibility of a solvent that occurs during dissolution. During an 
experiment, the introduction of the pellets into the BARDS system causes changes in the 
speed of sound in the dissolution medium, which can be monitored acoustically. The 
dissolution process thus generates a change in the resonance frequency time course of the 
solvent in the vessel. BARDS analysis has previously shown successful application in the 
analysis of powder blend uniformity (Fitzpatrick et al., 2012) and the profiling of enteric-
coated drug delivery systems (Fitzpatrick et al., 2014). 
Of vital importance to this work was to confirm that the active peptide retains its 
bioactivity post-encapsulation, as protein aggregation or denaturation may occur during 
formulation. In fluid-bed coating, inlet air temperature is partially negated due to the 
latent heat of evaporation of the coating polymer solvent during the spraying process (El 
Mafadi et al., 2005; Poncelet D, 2009). This leads to a milder micro-temperature at the 
surface of individual pellets than would be suggested by the process parameters 













activity of the untreated peptide. Compared to alternative methods of encapsulation which 
have been used for peptides incorporating solvent-based methods, we consider this to be 
a reasonable retention of activity in light of our processing conditions.  
In conclusion, a multiparticulate sustained release formulation approach for 
delivery of a ghrelin agonist peptide is described. Aqueous-based EC film coats applied 
to pellets in the millimetre size range are porous and mechanically brittle, leading to 
disintegration or “shelling” of the coat in aqueous media. Here, we observed that the high 
loading of a freely soluble ghrelin agonist peptide enhanced the problem of film 
disintegration due to increased osmotic pressure and pellet swelling. To overcome this, 
we provide near zero-order release by taking two alternative approaches: 1) Organic EC 
based solution can be applied to the pellets, or 2) an aqueous dispersion of a pH dependent 
MA co-polymer may be introduced as a subcoat to the aqueous EC. This provides an 
impermeable seal coat in gastric conditions which prevents fluid ingress into pellets, 
thereby preventing pressure-induced EC layer fracture and allowing the EC polymer to 
function as originally intended. Both processes allow the ghrelinergic peptide to retain 
sufficient activity after encapsulation. In conclusion, we designed a successful delivery 
formulation for a peptide based ghrelinergic dairy-derived bioactive hydrolysate. This 
delivery platform is suitable for progression to  pre-clinical rodent models to assess 
efficacy in vivo. 
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Figure 1A. Concentration response curve of novel whey-derived hydrolysate. 
Concentration response curves for the endogenous ghrelin receptor ligand, ghrelin, the 
whey-derived hydrolysate, FHI-2571 and the parent whey protein concentrate (WPC) 
measured in ghrelin receptor over-expressing HEK293A cells. Intracellular Ca2+ 
increase was depicted as a percentage of maximal Ca2+influx in relative fluorescence 
unit (RFU) as elicited by control (3.3% FBS). Graph represents mean ± SEM of three 
independent experiments performed in triplicate. Figure 1B: No activity of test 
compounds on wild-type cells. Activity of control (FBS), ghrelin, FHI-2571 and parent 
whey protein concentrate (WPC) in wild-type (HEK293A-WT) cells (representative of 

















Figure 2. Ghrelin receptor agonist, FHI-2571 displays pH dependent activity. Graph 
represents three independent experiments carried out in at least triplicate. Reduction in 
FHI-2571-mediated ghrelin receptor activation following exposure to acidic pH 
confirms the need for an oral delivery mechanism (Control = FHI-2571 not exposed to 















Figure 3. Dissolution study of aqueous-based Ethylcellulose and FHI-2571 
hydrolysate pellets. USP Type 1 (Basket) dissolution studies (50 rpm, 37.5 °C) showed 
a burst release in simulated conditions with >80% release over the first hour in both 
uncoated and coated FHI-2571 hydrolysate pellets following exposure to Simulated 
Gastric Fluid sine pepsin (SGFsp) pH 1.2 (A). Graph represents three independent 
experiments carried out in triplicate. Macroscopic investigation showed an unexpected 
disintegration or “shelling” of the coat from the pellets, resulting in rapid release of 















Figure 4. Dissolution study of FHI-2571 hydrolysate pellets with ethanolic-based 
ethylcellulose film coat and aqueous-based dual coat. Two different approaches were 
taken to circumvent the phenomenon of "shelling" as a result of coating with an aqueous 
dispersion of EC. 1) An organic solution of EC was applied to create a more robust coat, 
and 2) a methacrylic acid copolymer was layered beneath the aqueous EC to form a 
functional acid-resistant subcoat. USP Type 1 (Basket) dissolution studies (simulated 
gastric fluid, SGFsp, pH 1.2) showed effective delayed release for both organic EC and 
aqueous dual-coated pellets. Graph represents three independent experiments carried 
out in triplicate. 
 
Figure 5. Scanning Electron Microscope (SEM) images of whole pellets.  SEM 
images of uncoated (A), aqueous ethylcellulose (EC) coated (B), ethanolic EC coated 














Figure 6. Scanning Electron microscope (SEM) images of cross-sectioned pellets. 
Aqueous EC coated pellets have a distinctly porous coat which allows for water ingress 
and increased osmotic pressure within the pellet, leading to swelling and rupture of the 
film coat (A,B). Organic EC coated pellets display a more complete, non-porous coat 
(C,D), while the aqueous dual coated pellets show a distinct double layer, with the 















Figure 7. Modelling of release profiles in a pH transition setup. USP Type IV (Flow-
through) dissolution experiments were carried out using 22.6 mm diameter cells to 
quantify FHI-2571 release in a pH-transfer model (pH 1.2 to pH 6.8). A closed loop 
system maintained at 37 °C recirculated 100 ml of media at 4 ml/minute for the duration 
of the experiment (adapted from a previous study (Keohane et al., 2016)). This yielded a 
predictable sustained release for both organic EC coated and dual-coated pellets. Graph 
represents three independent experiments carried out in triplicate. Dashed line indicates 















Figure 8. Fundamental curve frequency of coated pellets in SGF. Fundamental curve 
frequency time course of uncoated (Δt = 167 s), aqueous-based EC coated (10% w/w) (Δt 
= 790 s), dual-coated (MaA and aqueous EC, 10% w/w, respectively), and organic-based 
EC (10% w/w) pellets, containing FHI-2571, in 25 mL SGFsp (pH 1.2). This data is 
representative of three independent experiments carried out, and demonstrates the 
comparable integrity of the dual-coated pellets with that of the organic-based EC pellets, 
in low pH conditions. Δt denotes the time at which minimal frequency reached (release) 















Figure 9. FHI-2571 retains bioactive functionality after encapsulation. Activity of 
FHI-2571 after encapsulation was determined relative to activity of non-encapsulated 
FHI-2571 on ghrelin receptor overexpressing HEK293A cell line (representative of four 
independent experiments carried out in at least triplicate). Activity was quantified as 















Table 1. Coating parameters. Coating parameters employed during the film coating 
with methacrylic acid and ethyl acrylate copolymer type C (Acryl-EZE® II), aqueous 
dispersion of ethylcellulose (Surelease® Type B), and organic solution of ethylcellulose 




10 % (w/w) 
Acry-LEZE® II 
in water 
11 % (w/w) 
Surelease® Type B 
in water 
5 % (w/w) 
Ethocel™ 
in 96 % (v/v) 
EtOH 
Liquid Feed Rate 
(g/minute) 
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